الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 94 |  |  |
| | | from | 94 | | |
Abstract
Non-alcoholic fatty liver syndrome is defined by the presence of macro vesicular dyslipidemia in at least 5% of hepatocytes in the absence of a secondary aetiology like alcohol or drugs (NAFLD). from nonalcoholic fatty liver disease through nonalcoholic steatohepatitis to fibrosis and cirrhosis, it addresses them all. (1). It’s well knowledge that being overweight might lead to the development of NAFLD (Hamilton et al., 2001). As reported by Festiet al. (2004). In recent years, NAFLD has surpassed all other causes of chronic liver disease as the leading cause of liver failure worldwide (Younossi et al.,2016). One-five percent of those with NAFLD develop hepatocellular carcinoma, and 4-8% develop cirrhosis. (HCC) There are both non-invasive (imaging, biomarkers) and invasive (liver biopsy) methods for detecting NAFLD/MAFLD, and the suggested criteria for the evaluation of MAFLD are dependent on evidence revealing hepatic steatosis, as reported in a 2016 research (Younossi et al.). Recent studies have indicated that bariatric surgery, the only effective treatment for very overweight people, may reduce liver damage (Lassailly et al., 2015). rapid and long-term weight reduction, and reduced risk of illness and mortality, have all been associated with it (Christou et al., 2005; Sjöström et al., 2007). Hepatic steatosis is another condition that 92% of patients have reported improvement or resolution of after undergoing bariatric surgery (Mummadiet al.,2008). The time course of these changes following surgery, however, is not well characterised (Wree et al.,2014).
Experts from all around the globe have come together to suggest a new name for the disorder known as metabolic (disruption) associated fatty liver disease (MAFLD) (Eslam et al.,2020).
New studies suggest that liver damage is reduced after bariatric surgery (Lassailly et al.,2015)
The purpose of this study was to evaluate the accuracy of non-invasive tests compared to a liver biopsy in identifying fibrosis in the liver of morbidly obese individuals with cirrhosis prior to bariatric surgery.
Cross-sectional study participants comprised people who came to our outpatient clinic in the weeks before their bariatric surgery; 8 men and 41 women were screened for MAFLD using abdominal ultrasonography.
Standard tests (complete blood count, creatinine levels, antigen levels, renal functions, Serum lipids, RBS, and haemoglobin A1c), as well as a liver biopsy, were performed on patients with fatty liver (fatty liver) on the day of operation.
Non-invasive techniques of evaluating fibrosis included the Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score (NFS), the — some individuals Score (FIB-4), and the AST to Platelet Amount Index (APRI).
Indicators of the following results were found:
To begin, there is an association between obesity and a higher risk of developing MAFLD.
The number of instances where NO FIBROSIS was indicated by liver histology was 28, while the numbers were FIB4 (48), APRI (47), and NFS (19) respectively. 2.Fat accumulation in the liver was detected in all cases by abdominal ultrasonography, but in only 27 of 58 biopsies (54%).
Liver biopsies revealed 17 instances of mild to moderate fibrosis, whereas FIB4 detected just one.
The liver biopsies showed that just one patient had significant fibrosis, although the NFS and the invasive test both showed that three individuals had (APRI).